Akiko Watanabe

发表

Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment

Takako Shimizu, M. Yamada, H. Ishizuka, 2021, European journal of clinical pharmacology.

Effect of ion suppression on judgment of enzyme inhibition and avoidance of error by utilizing a stable isotope-labeled probe substrate: example of CYP3A4 inhibition with [13C4,15N] labeled midazolam as a substrate.

N. Okudaira, K. Sudo, O. Okazaki, 2007, Drug metabolism and pharmacokinetics.

Analysis of Mechanism-Based Inhibition of CYP 3A4 by a Series of Fluoroquinolone Antibacterial Agents

H. Kusuhara, H. Takakusa, O. Ando, 2016, Drug Metabolism and Disposition.

Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan

Mark Lee, F. LaCreta, M. Abutarif, 2021, Clinical and translational science.

Difference in Mechanism-Based Inhibition of Cytochrome P450 3A4 and 3A5 by a Series of Fluoroquinolone Antibacterial Agents

H. Kusuhara, H. Takakusa, O. Ando, 2017, Drug Metabolism and Disposition.

DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats

Koji Matsumoto, K. Chiba, Y. Ishimoto, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Quantitative analysis of mRNA expression levels of aldo-keto reductase and short-chain dehydrogenase/reductase isoforms in human livers.

Kengo Watanabe, T. Fukami, M. Nakajima, 2020, Drug metabolism and pharmacokinetics.

Quantitative Evaluation of the Contribution of Each Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoform to Reduction Reactions of Compounds Containing a Ketone Group in the Human Liver

Kengo Watanabe, T. Fukami, M. Nakajima, 2022, Drug Metabolism and Disposition.

Thrombolytic properties of an immunoconjugate between single-chain urokinase-type plasminogen activator (scu-PA) and F(ab′)2 of bispecific monoclonal antibody against fibrin and against u-PA in hamsters

A. Kakinuma, T. Kurokawa, Akiko Watanabe, 1994 .

Species differences between rats and primates (humans and monkeys) in complex cleavage pathways of DS-8500a characterized by 14C-ADME studies in humans and monkeys after administration of two radiolabeled compounds and in vitro studies.

Manabu Kato, H. Takakusa, D. Nakai, 2022, Drug metabolism and pharmacokinetics.

In vivo multiple metabolic pathways for a novel G protein-coupled receptor 119 agonist DS-8500a in rats: involvement of the 1,2,4-oxadiazole ring-opening reductive reaction in livers under anaerobic conditions

H. Yamazaki, O. Ando, N. Watanabe, 2018, Xenobiotica; the fate of foreign compounds in biological systems.

DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models

T. Agatsuma, T. Maejima, T. Shibutani, 2022, Molecular cancer therapeutics.

Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models

Kengo Watanabe, S. Yamashita, M. Yamada, 2020, Drug Metabolism and Disposition.

Combination of GSH Trapping and Time-Dependent Inhibition Assays as a Predictive Method of Drugs Generating Highly Reactive Metabolites

Kazuhito Shiosakai, T. Izumi, H. Takakusa, 2011, Drug Metabolism and Disposition.

Microsoft Word-74715577-file00

Kazuhito Shiosakai, H. Takakusa, N. Okudaira, 2011 .

Combination of glutathione trapping and time-dependent inhibition assays as a predictive method drugs generating highly reactive metabolites

Kazuhito Shiosakai, T. Izumi, H. Takakusa, 2011 .

Risk Assessment for Drug-Drug Interaction Caused by Metabolism-Based Inhibition of CYP3A Using Automated in Vitro Assay Systems and Its Application in the Early Drug Discovery Process

N. Okudaira, K. Sudo, O. Okazaki, 2007, Drug Metabolism and Disposition.

Effect of DS-8500a, a Novel G Protein-Coupled Receptor 119 Agonist, on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects

T. Taguchi, H. Furuie, Manabu Kato, 2019, Clinical Drug Investigation.

Fibrinolytic potential of DS-1040, a novel orally available inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa).

Y. Morishima, N. Miyoshi, Akiko Watanabe, 2018, Thrombosis research.